Drug intelligence / Profile preview

RGS-365

Development stage: Preclinical
Lead developer: RNAGene
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RGS-365 is a preclinical-stage immunostimulant developed by RNAGENE, Inc., a biotechnology company specializing in RNA-based therapeutics. The drug is designed for the treatment of solid tumors by activating the innate immune system within the tumor microenvironment. RGS-365 utilizes RNAGENE's proprietary RNA-based Gene Stimulation (RGS) technology, which aims to trigger robust anti-tumor immune responses. As of 2024, the asset remains in early-stage development, with the specific molecular target and RNA architecture (such as a RIG-I agonist or TLR ligand) not yet publicly detailed in clinical literature.

Targets

TLR (Toll-like receptors)

Beyond the preview

Go deeper on RGS-365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGS-365.

Explore the full profile